Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other financing activities (2022 - 2025)

Historic Other financing activities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$285000.0.

  • Taysha Gene Therapies' Other financing activities fell 7065.87% to -$285000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$204000.0, marking a year-over-year decrease of 14615.38%. This contributed to the annual value of -$167000.0 for FY2024, which is 14185.46% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Other financing activities stood at -$285000.0 for Q3 2025, which was down 7065.87% from $118000.0 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Other financing activities registered a high of $652000.0 during Q4 2023, and its lowest value of -$640000.0 during Q3 2023.
  • Over the past 4 years, Taysha Gene Therapies' median Other financing activities value was -$55000.0 (recorded in 2024), while the average stood at -$75500.0.
  • As far as peak fluctuations go, Taysha Gene Therapies' Other financing activities tumbled by 122280.7% in 2023, and later soared by 100769.23% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Other financing activities stood at -$333000.0 in 2022, then skyrocketed by 295.8% to $652000.0 in 2023, then tumbled by 93.4% to $43000.0 in 2024, then plummeted by 762.79% to -$285000.0 in 2025.
  • Its last three reported values are -$285000.0 in Q3 2025, $118000.0 for Q2 2025, and -$80000.0 during Q1 2025.